Lenalidomide (trade name Revlimid) is a derivative of thalidomide introduced in 2004.
It was initially intended as a treatment for multiple myeloma – a cancer of the blood - , for which thalidomide ‘is an accepted therapeutic treatment’. Lenalidomide has also been used for the class of hematological disorders known as myelodysplastic syndromes (MDS). Toxicity remains an issue for users. It costs $163,381 per year for the average patient.
On Dec, 29, 2016 117,888 people reported to have side effects when taking Revlimid.
Among them, 261 people (0.22%) have Hallucination
Time on Revlimid when people have Hallucination :
| |
< 1 month |
1 - 6 months |
6 - 12 months |
1 - 2 years |
2 - 5 years |
5 - 10 years |
10+ years |
| Hallucination |
60.00% |
32.73% |
3.64% |
1.82% |
1.82% |
0.00% |
0.00% |
Gender of people who have Hallucination when taking Revlimid :
| |
Female |
Male |
| Hallucination |
40.96% |
59.04% |
Age of people who have Hallucination when taking Revlimid :
| |
0-1 |
2-9 |
10-19 |
20-29 |
30-39 |
40-49 |
50-59 |
60+ |
| Hallucination |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
1.29% |
9.68% |
89.03% |
On Dec, 22, 2016 117,888 people reported to have side effects when taking Revlimid.
Among them, 12,529 people (10.63%) have Death
Time on Revlimid when people have Death :
| |
< 1 month |
1 - 6 months |
6 - 12 months |
1 - 2 years |
2 - 5 years |
5 - 10 years |
10+ years |
| Death |
33.48% |
42.12% |
12.42% |
7.66% |
4.32% |
0.00% |
0.00% |
Gender of people who have Death when taking Revlimid :
| |
Female |
Male |
| Death |
41.81% |
58.19% |
Age of people who have Death when taking Revlimid :
| |
0-1 |
2-9 |
10-19 |
20-29 |
30-39 |
40-49 |
50-59 |
60+ |
| Death |
0.00% |
0.01% |
0.00% |
0.26% |
0.58% |
3.32% |
11.93% |
83.90% |
